Education
About Us
Working with TipRanks
Follow Us
Novartis (CH:NOVN)
:NOVN
NOVN Stock Chart & Stats
Day’s Range― - ―
52-Week RangeCHF81.10 - CHF104.62
Previous CloseN/A
Volume858.75K
Average Volume (3M)2.46M
Market Cap
CHF197.90B
Enterprise ValueCHF208.96B
Total Cash (Recent Filing)CHF7.00B
Total Debt (Recent Filing)CHF32.64B
Price to Earnings (P/E)17.4
Beta0.86
Next Earnings
Oct 28, 2025EPS Estimate
1.81Last Dividend Ex-Date
Mar 11, 2025Dividend Yield3.37%
Share Statistics
EPS (TTM)1.95
Shares Outstanding2,112,421,900
10 Day Avg. Volume2,058,912
30 Day Avg. Volume2,463,732
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF102.50Price Target Upside-1.42% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering13
Bulls Say, Bears Say
Bulls Say
Growth PotentialThere is potential for an upgrade cycle driven mainly by Kisqali, Scemblix, and Pluvicto.
Pipeline OpportunitiesAnalysts see the pipeline as high risk-reward with promising opportunities in areas like cardiovascular disease and IgA nephropathy.
Product SuccessNovartis announced positive topline data for ianalumab in both NEPTUNUS 1 and 2 trials in Sjogren’s syndrome, an autoimmune disease with a significant patient population and unmet need given the lack of any approved treatment options.
Bears Say
Growth OutlookDespite likely EPS momentum and a decent catalyst path, analysts remain cautious due to the lower growth outlook and patent exposure.
Patent ChallengesThere is more to be done in the face of $32bn in sales which faces generic competition out to 2030.
Valuation ConcernsAnalyst remains neutral on valuation, with the target price-to-earnings ratio higher than what would be implied by the forecasted growth rate.
Novartis AG News
NOVN FAQ
What was Novartis’s price range in the past 12 months?
Novartis lowest stock price was CHF81.10 and its highest was CHF104.62 in the past 12 months.
What is Novartis’s market cap?
Novartis’s market cap is CHF197.90B.
When is Novartis’s upcoming earnings report date?
Novartis’s upcoming earnings report date is Oct 28, 2025 which is in 50 days.
How were Novartis’s earnings last quarter?
Novartis released its earnings results on Jul 17, 2025. The company reported CHF1.946 earnings per share for the quarter, beating the consensus estimate of CHF1.89 by CHF0.055.
Is Novartis overvalued?
According to Wall Street analysts Novartis’s price is currently Overvalued.
Does Novartis pay dividends?
Novartis pays a Annually dividend of CHF3.5 which represents an annual dividend yield of 3.37%. See more information on Novartis dividends here
What is Novartis’s EPS estimate?
Novartis’s EPS estimate is 1.81.
How many shares outstanding does Novartis have?
Novartis has 2,112,421,900 shares outstanding.
What happened to Novartis’s price movement after its last earnings report?
Novartis reported an EPS of CHF1.946 in its last earnings report, beating expectations of CHF1.89. Following the earnings report the stock price went down -1.871%.
Which hedge fund is a major shareholder of Novartis?
Currently, no hedge funds are holding shares in CH:NOVN
Company Description
Novartis
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
NOVN Stock 12 Month Forecast
Average Price Target
CHF102.50
▼(-1.42% Downside)
Technical Analysis
Options Prices
Currently, No data available
---